Herantis Pharma
1,22
EUR
+1,67 %
HRTIS
First North Finland
Biotechnology & Pharmaceuticals
Health Care
4.155 investorer følger denne virksomhed
+1,67%
-2,01%
-15,28%
-19,74%
-12,86%
-22,54%
-27,81%
-56,37%
-81,67%
-87,89%
herantis.com/investors
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Læs mereP/E (adj.) (24e)
-4,68
EV/EBIT (adj.) (24e)
-4,69
P/B (24e)
117,13
Udbytteafkast, % (24e)
-
Kursmål
2.20 EUR
Anbefaling
Akkumulér
Opdateret
23.8.2024
First North Finland
HRTIS
Daglig lav / høj pris
1,215 / 1,22
EUR
Markedsværdi
24,6 mio. EUR
Aktieomsætning
2,91 t EUR
Volumen
2,4 t
Business risk
Valuation risk
Current
Previous
Seneste analyser
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalytiker
Antti Siltanen
Analytiker
Resultatopgørelse
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Omsætning | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| vækst-% | 150,0 % | |||||||
| EBITDA | -8,5 | -9,7 | -8,1 | 0,2 | -5,3 | -5,0 | -5,4 | -6,0 |
| EBIT (adj.) | -8,1 | -12,5 | -8,0 | 0,2 | -5,3 | -5,0 | -5,4 | -6,0 |
| EBIT | -8,1 | -12,5 | -8,0 | 0,2 | -5,3 | -5,0 | -5,4 | -6,0 |
| Overskud før skat | -8,6 | -12,8 | -9,3 | 0,3 | -5,3 | -5,0 | -5,4 | -6,0 |
| Netto indkomst | -8,6 | -12,8 | -9,3 | 0,3 | -5,3 | -5,0 | -5,4 | -6,0 |
| EPS (adj.) | -0,88 | -1,15 | -0,55 | 0,01 | -0,26 | -0,21 | -0,23 | -0,25 |
| vækst-% | -1.983,9 % | |||||||
| Udbytte | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Udbytte ratio |
Lønsomhed og afkast på kapital
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| EBITDA-% | -213.375,0 % | -243.525,0 % | -201.825,0 % | 3.850,0 % | -52.560,0 % | -49.520,0 % | -54.342,5 % | -59.532,9 % |
| EBIT-% (adj.) | -201.775,0 % | -311.525,0 % | -199.825,0 % | 3.850,0 % | -52.560,0 % | -49.520,0 % | -54.342,5 % | -59.532,9 % |
| EBIT-% | -201.775,0 % | -311.525,0 % | -199.825,0 % | 3.850,0 % | -52.560,0 % | -49.520,0 % | -54.342,5 % | -59.532,9 % |
| ROE | -226,6 % | -396,1 % | 1.541,2 % | 12,0 % | -213,4 % | -2.116,2 % | 221,0 % | 73,0 % |
| ROI | -109,1 % | -119,5 % | -151,8 % | 3,3 % | -139,4 % | -180,1 % | -362,3 % | -2.381,3 % |
Værdiansættelse
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Aktiekurs (EUR) | 4,15 | 2,40 | 1,65 | 1,58 | 1,22 | 1,22 | 1,22 | 1,22 |
| Aktier | 9,8 | 11,1 | 16,9 | 20,2 | 20,2 | 23,9 | 23,9 | 23,9 |
| Markedsværdi | 40,5 | 26,6 | 27,9 | 31,9 | 24,6 | 29,1 | 29,1 | 29,1 |
| Enterprise value | 34,4 | 26,4 | 26,5 | 25,4 | 24,6 | 29,1 | 34,5 | 40,5 |
| EV/S | 8.593,4 | 6.606,4 | 6.613,7 | 6.360,3 | 2.463,6 | 2.910,2 | 3.453,7 | 4.049,0 |
| EV/EBITDA | - | - | - | 165,2 | - | - | - | - |
| EV/EBIT (adj.) | - | - | - | 165,2 | - | - | - | - |
| EV/EBIT | - | - | - | 165,2 | - | - | - | - |
| P/E (adj.) | - | - | - | 114,2 | - | - | - | - |
| P/E | - | - | - | 114,2 | - | - | - | - |
| P/B | 5,3 | - | - | 6,8 | 117,1 | 112,8 | - | - |
| P/S | 10.122,9 | 6.662,4 | 6.976,2 | 7.963,6 | 2.459,6 | 2.911,0 | 2.911,0 | 2.911,0 |
| Udbytteprocent | ||||||||
| Equity ratio | 46,2 % | -14,7 % | -1,1 % | 69,9 % | 7,6 % | 9,4 % | -2.070,5 % | -4.451,8 % |
| Gearing ratio | -80,6 % | 19,6 % | 2.071,4 % | -136,0 % | 19,0 % | -3,1 % | -104,8 % | -102,2 % |
Kvartalsdata
| Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
|---|---|---|---|---|---|---|---|---|---|
| Omsætning | 0,0 | 0,0 | 0,0 | ||||||
| EBITDA | -2,4 | 2,6 | 0,2 | -2,8 | -2,5 | ||||
| EBIT | -2,4 | 2,6 | 0,2 | -2,8 | -2,5 | ||||
| Overskud før skat | -1,8 | 2,1 | 0,3 | -2,8 | -2,5 | ||||
| Netto indkomst | -1,8 | 2,1 | 0,3 | -2,8 | -2,5 |
ViserAlle indholdstyper
Herantis Pharma has successfully completed the Part 1 of the Phase 1b clinical trial
Herantis Pharma Oyj: Herantis Pharma will present at the BioStock Life Science Summit, November 20
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Herantis R&D webinar complemented scientific background and roadmap
Herantis Pharma: Key messages from today’s R&D webinar
Herantis clinical trial started as planned
Herantis Pharma: HER-096 dosing started in the Phase 1b trial
Herantis Pharma to host R&D webinar on October 23, 2024
Composition of Herantis Pharma Plc's Shareholders' Nomination Committee
Probabilities of success in drug development
Herantis: New research data
Herantis Pharma: Structural rationale of HER-096 design published in Nature Communications
Clinical phases of drug development
Herantis receives approval for Phase Ib clinical trial
Herantis Pharma announces approval of clinical trial application for a Phase 1b trial with HER-096 in Parkinson’s disease
Herantis Pharma participating at Sachs, Nordic Life Science days and Finnish investor conferences in August and September
Herantis H1'24: The next trial phase will begin in H2 as expected
Herantis H1'24 flash comment: Phase Ib starts at the end of the year
Herantis Pharma, Webcast, Q2'24
